Vaginal Probiotic Capsule Composition for Faster Infection Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral administration of probiotics for vaginal infections is inefficient, with high mortality rates due to the harsh gastric environment and requires prolonged treatment durations, while vaginal applicators can cause insertion injuries and mucosal irritation.
Innovation Solution
A composition comprising Lactobacillus crispatus and other probiotics in a hardshell capsule form, with prebiotic excipients like skim milk, is designed for direct vaginal application, ensuring optimal CFU dosage and rapid delivery to the vaginal environment, avoiding gastric transit and reducing insertion complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If probiotics are administered orally, then the treatment can be convenient and easy to take, but the probiotic organisms suffer high mortality rates due to the harsh gastric environment and require prolonged treatment durations
Solution Approach 1:
The patent uses a vaginal applicator as an intermediary device to deliver probiotics directly to the vaginal environment, bypassing the harsh gastric system. This mediator allows probiotic organisms to reach their target site without exposure to stomach acid and digestive enzymes, thereby maintaining high survival rates while keeping administration convenient.
2Ease of operation
If probiotics are administered orally, then the treatment can be convenient, but it requires prolonged treatment durations of 30 to 60 days
Solution Approach 1:
The patent extracts the probiotic delivery from the gastrointestinal tract and places it directly into the vaginal environment. By taking out the intermediate step of oral digestion and direct delivery to the target site, the treatment achieves much faster results (5-10 days vs. 30-60 days) while maintaining ease of administration through the vaginal route.
3Speed
If vaginal applicators are used to deliver solid dosage form, then direct delivery to the site of action is achieved, but vaginal insertion injury and mucosal irritation can occur
Solution Approach 1:
The patent changes the physical state of the probiotic formulation from solid dosage form to a liquid or semi-liquid composition. This parameter change allows the probiotics to be delivered in a form that is less mechanically traumatic to vaginal tissues, reducing insertion injury and mucosal irritation while maintaining rapid delivery to the site of action through the vaginal applicator.
Data Source
AI summary
A composition adapted for use within a vagina, the composition comprising: Lactobacillus crispatus and one probiotic selected from the group consisting of: Lactobacillus rhamnosus, Lactobacillus reuteri, and Lactobacillus gasseri.